- Home
- APVO vs SGLY Comparison
APVO vs SGLY Comparison
Compare APVO & SGLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- SGLY
- Stock Information
- Founded
- APVO 2016
- SGLY 2001
- Country
- APVO United States
- SGLY United States
- Employees
- APVO N/A
- SGLY N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- SGLY
- Sector
- APVO Health Care
- SGLY
- Exchange
- APVO Nasdaq
- SGLY Nasdaq
- Market Cap
- APVO 4.1M
- SGLY 4.5M
- IPO Year
- APVO N/A
- SGLY 2008
- Fundamental
- Price
- APVO $1.61
- SGLY $1.04
- Analyst Decision
- APVO Strong Buy
- SGLY
- Analyst Count
- APVO 1
- SGLY 0
- Target Price
- APVO $5,920.00
- SGLY N/A
- AVG Volume (30 Days)
- APVO 162.7K
- SGLY 44.9K
- Earning Date
- APVO 11-06-2025
- SGLY 09-26-2025
- Dividend Yield
- APVO N/A
- SGLY N/A
- EPS Growth
- APVO N/A
- SGLY N/A
- EPS
- APVO N/A
- SGLY N/A
- Revenue
- APVO N/A
- SGLY $2,172,036.00
- Revenue This Year
- APVO N/A
- SGLY N/A
- Revenue Next Year
- APVO N/A
- SGLY N/A
- P/E Ratio
- APVO N/A
- SGLY N/A
- Revenue Growth
- APVO N/A
- SGLY N/A
- 52 Week Low
- APVO $1.54
- SGLY $0.54
- 52 Week High
- APVO $381.10
- SGLY $5.49
- Technical
- Relative Strength Index (RSI)
- APVO 28.32
- SGLY 49.06
- Support Level
- APVO $1.56
- SGLY $1.01
- Resistance Level
- APVO $1.73
- SGLY $1.22
- Average True Range (ATR)
- APVO 0.14
- SGLY 0.10
- MACD
- APVO 0.02
- SGLY 0.00
- Stochastic Oscillator
- APVO 11.29
- SGLY 41.97
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.